Recently, the Class-1 innovative drug Alfosbuvir Tablets (Chinese trade name:圣诺迪) of Nanjing Sanhome Pharmaceutical Co., Ltd. is approved for marketing through the priority review and approval procedure by China NMPA. It is an innovative drug independently developed in China with independent intellectual property rights. Used in combination with daclatasvir hydrochloride, it is indicated for the treatment of chronic hepatitis C virus (HCV) of genotype 1, 2, 3 and 6 infection for adults who are initially treated or have been treated with interferon, combined with or without compensatory cirrhosis.

Alfosbuvir is an inhibitor for HCV NS5B RNA-depended polymerase (necessary for virus replication). It is a nucleotide precursor drug, metabolized into pharmacologically active metabolites (SH229M3) in the cell, which can be embedded into HCV RNA by NS5B polymerase to terminate replication. The marketing of this drug provides a new treatment option for adult patients with chronic HCV infection.